Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.98 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.98 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | PRNP | P04156 | 2/20 | 0.98 |
| ▸ | MTOR | P42345 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | APP | P05067 | 1/20 | 0.98 |
| ▸ | NQO2 | P16083 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Chloroquine SCHEMBL134500 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8933 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL29363614 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8934 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL8474661 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| (R)-Chloroquine SCHEMBL29429108 | 0.99 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL23854336 | 0.98 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL3302947 | 0.98 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL9862220 | 0.98 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Chloroquine SCHEMBL22534361 | 0.98 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225213-A1 | Nucleic acid carriers for delivery of therapeutic agents | KOSAK MATTHEW K | 2007-09-27 | — | — | US | disclosed |
| US-6982252-B2 | Inhibition of vacuolar proton ATPase activity and/or the modulation of acidic organelle function sensitizes cells to radiation, chemotherapy and biological agents | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2006-01-03 | — | — | US | disclosed |
| US-20030224403-A1 | Lethal toxin cytopathogenicity and novel approaches to anthrax treatment | PEQUOT PRIVATE EQUITY FUND III, L.P. | 2003-12-04 | — | — | US | disclosed |
| WO-2003047350-A1 | INHIBITION OF VACUOLAR PROTON ATPASE AND/OR MODULATION OF ACIDIC ORGANELLE FUNCTION SENSITIZES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20020156025-A1 | Inhibition of vacuolar proton ATPase activity and/or the modulation of acidic organelle function sensitizes cells to radiation, chemotherapy and biological agents | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2002-10-24 | — | — | US | disclosed |
| EP-0910632-A2 | PRESENTATION OF ANTIGEN, INTRODUCED INTO THE CELLS BY STIMULATION OF MACROPINOCYTOSIS | THE UNIVERSITY OF DUNDEE, UNIVERSITY COURT (GB) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997023607-A2 | PRESENTATION OF ANTIGEN, INTRODUCED INTO CELLS BY STIMULATION OF MACROPINOCYTOSIS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156025-A1 | Inhibition of vacuolar proton ATPase activity and/or the modulation of acidic organelle function sensitizes cells to radiation, chemotherapy and biological agents | ATP6V1H, ATP6V1E1, ATP6AP1 | CHRM2 4621/4885CHRM4 4585/4885CHRM5 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.